PRF Technologies Finalizes Highly Dilutive $10M Equity Line with YA II PN, LTD., Registering 345% of Outstanding Shares for Resale
PRFX is trading near its 52-week low of $1.41 (7.1% above the low).
Summary
PRF Technologies has finalized a highly dilutive equity line agreement to raise up to $10.0 million, registering 3,000,000 shares for resale by YA II PN, LTD., representing 345% of current outstanding shares.
Key Events · Financing and Capital Events · PRFX
-
Equity Line Agreement Finalized
This 424B3 prospectus supplement finalizes the terms of the Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD., previously announced on May 7, 2026, and registered via an F-1 on May 13, 2026. The company may sell up to $10.0 million in ordinary shares to YA over 36 months.
-
Massive Potential Dilution
The filing registers 3,000,000 ordinary shares for resale by YA, including 2,975,616 'Advance Shares' that the company may sell to YA. This represents approximately 345% of the 868,756 ordinary shares outstanding as of May 12, 2026, indicating extreme potential dilution for existing shareholders.
-
Discounted Share Sales
Shares sold to YA under the agreement will be priced at 97% of the lowest of the three daily volume-weighted average prices (VWAPs) during a pricing period, reflecting a significant discount to market prices.
-
Capital for Operations
Proceeds from the company's sales to YA will be used for research and development costs, working capital, and general corporate purposes, providing a critical funding source for the micro-cap company.
Analysis · PRFX · Life Sciences
This prospectus supplement finalizes the terms for a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD., allowing PRF Technologies to sell up to $10.0 million in ordinary shares to YA over 36 months. The filing registers 3,000,000 shares for resale by YA, which represents approximately 345% of the company's current outstanding shares. This level of potential dilution is extremely significant for existing shareholders, especially given the company's micro-cap status. Shares sold to YA will be at a discount (97% of the lowest VWAP), indicating a high cost of capital. While the agreement provides a crucial funding source for R&D and working capital, the terms are highly dilutive and will likely exert substantial downward pressure on the stock price.
At the time of this filing, PRFX was trading at $1.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $1.41 to $17.95. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.